February / March #68 : Feed Your Head

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

A Daily Affirmation

Feed Your Head

TO: President George Bush

Puppet Masters

License to ddI

Longtime Companions: Tips For Two

You Sexy Thing

Indiana Jonesing

The Hanging CHAT

A Play In the Life

You Schmooze, You Lose

I Want My HIV

Speak Out

Once and Again


Redemption Song

Art from the Heart

S.O.S: Mouth Off

Zen at Work



Suck It Up

Comfort Zone

His M.O. is Her N-0

Sean's Trough Luck

Soul Survivors

Dyke Strike

A Rage to Age

Blood Brothers


02.16.90 Radiant Baby


Total Discord

Choosing Our Religion

Dogma & Devotion

The Brain Drain

Liver Lovers

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

February / March 2001

Feed Your Head

While HAART remains the main course of any treatment menu for CMC, experimental approaches may be

While HAART remains the main course of any treatment menu for CMC, experimental approaches may be useful on the side or even alone. Some block toxins pumped out by HIV-infected immune cells that likely cause neuron death; others protect the neurons from the damage done by those poisons.

  • Memantine, a drug approved in Germany to treat Parkinson's disease and dementia in the elderly, is thought to work by blocking the neurotoxin quinolinic acid. A federal trial for people with CMC is nearing completion.
  • Lexipasant, an experimental drug believed to block another neurotoxin, platelet activating factor, showed a trend toward cognitive improvements in a small study of people with CMC. A larger trial by DevCo begins soon.
  • CPI-1189 has been shown to counter tumor necrosis factor (TNF), a chemical secreted by activated immune cells that can injure neurons. A federal trial of this drug for CMC was recently concluded, and results are due soon.
  • Antioxidants are believed to protect neurons from injury by reducing levels of cell-damaging "free radicals," which are produced by the immune system's anti-HIV response and implicated in similar conditions such as Alzheimer's. Selegiline (a.k.a deprenyl), approved for Parkinson's, has demonstrated improvements in CMC symptoms in two small studies; a larger federal trial of the patch version is now enrolling. Gingko biloba, an herbal extract, has proved effective in rolling back symptoms of early-stage Alzheimer's dementia. Some practitioners have reported benefits for their patients with CMC.
  • Peptide T, the first computer-designed antiretroviral and the first HIV fusion inhibitor, has been shown to prevent neuron death by blocking gp120, a potent HIV toxin; the drug also reduces TNF. Results of a federal trial published in 1998 showed that HIVers with CMC who took Peptide T for six months had "overall cognitive improvement," while "overall deterioration was more common among the placebo group." But a widely publicized 1995 federal press release based on incomplete results of the same study claimed "there was no evidence that Peptide T had an effect."
  • Nimodipine (Nimotop), a calcium-channel blocker approved for treating cerebral hemorrhages, was thought to counteract the toxic effects of gp120, but has proved disappointing as a CMC treatment.

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.